Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
Honig S, Gittelman M, Kaminetsky J, Wang C, Amory J, Rohowsky N, Dudley R, Woun Seo B, Newmark J, Swerdloff R. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety. The Journal Of Sexual Medicine 2022, 19: 1750-1758. PMID: 37057401, DOI: 10.1016/j.jsxm.2022.09.002.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedHumansHypogonadismLibidoMaleMiddle AgedSexual BehaviorTestosteroneYoung AdultConceptsTestosterone replacement therapyPsychosexual Daily QuestionnaireLiver function testsOral TUSerum T concentrationsSexual functionT concentrationsTU therapyHypogonadal menFunction testsEffective long-term treatment optionProstate-specific antigen levelHigh-density lipoprotein cholesterolLong-term treatment optionAdult hypogonadal menOral testosterone undecanoateTotal testosterone levelsSystolic blood pressureTotal T concentrationsActive-controlled trialYears of treatmentLong-term safetySignificant changesEugonadal rangeCardiovascular endpoints